Evidence map›Paper›PMID 32887946›Full record

ReviewNature reviews. Microbiology2021

Gut microbiota in human metabolic health and disease.

Yong Fan, Oluf Pedersen

5 registry-linked trialsOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 2,620 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,620citing papers in PubMed, 3 pooled it
167.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03627910 naunknown statusnot on this map

Pressure Ulcers in Patients Receiving Enteral Nutrition Therapy. What is the Relationship With Gut Microbiota?

TypeinterventionalSponsorFondazione Don Carlo Gnocchi ETSRan2017 to 2022Enrolled30ConditionsMalnutrition, Pressure UlcerArmssymbiotic, zinc and arginine
NCT05199649 naunknown statusnot on this map

Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora

TypeinterventionalSponsorThe First Affiliated Hospital of Soochow UniversityRan2021 to 2023Enrolled30ConditionsEsophageal Squamous Cell Carcinoma, Intestinal FloraArmsSintilimabCombined With Chemotherapy
NCT05603403 phase4completednot on this mapstarted 2022, after this paper: background citation

Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

TypeinterventionalSponsorAzidus BrasilRan2022 to 2023Enrolled150ConditionsSigns and Symptoms, DigestiveArmsProbiatop, Placebo
NCT05668104 nacompletednot on this mapstarted 2023, after this paper: background citation

Jing Si Herbal Tea Liquid Packet in the Treatment of Dyspeptic Symptoms and Psychophysical Burden in Patients With Disorders of Long-Coronavirus Disease(COVID) Gut-brain Interaction --a Double-blind, Randomized, Placebo Controlled Study

TypeinterventionalSponsorBuddhist Tzu Chi General HospitalRan2023 to 2023Enrolled32ConditionsHealthy Subjects, COVID-19 Pneumonia, Irritable Bowel Syndrome, Functional Gastrointestinal DisordersArmsJing Si Herbal Tea Liquid Packet, Jing Si Herbal Tea Liquid Packet Placebo
NCT06795607 nacompletednot on this mapstarted 2024, after this paper: background citation

Interventional, Randomized, Single-blind, Placebo-controlled Study to Evaluate the Effect of a Probiotic Formulation Based on SF68® on Body Composition and Low-to-moderate Cardiovascular Risk

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria CareggiRan2024 to 2024Enrolled40ConditionsOverweight and ObesityArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

2,620 citing papers in PubMed, 3 syntheses or guidelines pooled it, 4,353 citations in OpenAlex.

  1. Effects of Weight Loss Interventions on Gut Microbiota-Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Effect ofNutrients · 2026
    Trial
  8. Gut microbes · 2026
    Article
  9. Gut microbes · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

2,560 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yong FanNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-4813-7017
Oluf PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. oluf@sund.ku.dk.ORCID http://orcid.org/0000-0002-3321-3972
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Observational findings achieved during the past two decades suggest that the intestinal microbiota may contribute to the metabolic health of the human host and, when aberrant, to the pathogenesis of various common metabolic disorders including obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases and malnutrition. However, to gain a mechanistic understanding of how the gut microbiota affects host metabolism, research is moving from descriptive microbiota census analyses to cause-and-effect studies. Joint analyses of high-throughput human multi-omics data, including metagenomics and metabolomics data, together with measures of host physiology and mechanistic experiments in humans, animals and cells hold potential as initial steps in the identification of potential molecular mechanisms behind reported associations. In this Review, we discuss the current knowledge on how gut microbiota and derived microbial compounds may link to metabolism of the healthy host or to the pathogenesis of common metabolic diseases. We highlight examples of microbiota-targeted interventions aiming to optimize metabolic health, and we provide perspectives for future basic and translational investigations within the nascent and promising research field.

Indexed as

Disease SusceptibilityEnergy MetabolismGastrointestinal MicrobiomeHealthAnimalsBiodiversityHumansMetabolic Diseases

Identifiers

PMID32887946
OpenAlexW3083241614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.